Cadisegliatin's CATT1 Phase 3 readout will determine whether a BTD-designated insulin adjunct can redefine T1D management

vTv Therapeutics is a clinical-stage company developing cadisegliatin, a targeted diabetes drug, to be used alongside insulin in adults with type 1 diabetes; the drug is not yet approved.

Cadisegliatin is a small-molecule GLP-1R/GIP receptor agonist with Breakthrough Therapy Designation, being evaluated as adjunctive insulin therapy in adults with Type 1 diabetes. The thesis resolves on CATT1 Phase 3 topline data in H2 2026 showing statistically significant HbA1c reduction versus placebo on a background of insulin. The primary competitive risk is that approved adjunctive T1D agents — notably SGLT2 inhibitors like Farxiga used off-label — set a meaningful efficacy and safety bar, while the absence of prior Phase 3 success for this mechanism leaves clinical validation unproven.